NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $2.53 -0.12 (-4.53%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.51 -0.02 (-0.79%) As of 09/19/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.53▼$2.6750-Day Range$2.36▼$3.1852-Week Range$2.25▼$4.18Volume51,278 shsAverage Volume26,342 shsMarket Capitalization$8.68 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision. The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders. KIO-100 has completed initial Phase 1 safety studies, demonstrating tolerability and preliminary signs of localized immune modulation without systemic exposure. Kiora’s second program, KIO-301, leverages optogenetic therapy to introduce light-sensitive proteins into retinal cells, offering a potential treatment for retinitis pigmentosa and other degenerative retinal diseases. This platform aims to restore visual function by converting surviving retinal neurons into artificial photoreceptors, and it is currently advancing through preclinical development and manufacturing scale-up. Headquartered in the United States, Kiora collaborates with academic institutions and contract research organizations to support its clinical and preclinical programs. The company’s leadership team comprises experienced executives and scientists drawn from both ophthalmology and biotechnology sectors, all working toward delivering novel treatments for patients with unmet visual needs.AI Generated. May Contain Errors. Read More Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreKPRX MarketRank™: Kiora Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingKiora Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialKiora Pharmaceuticals has a consensus price target of $10.00, representing about 295.3% upside from its current price of $2.53.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.28 to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiora Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiora Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.32% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 84.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.32% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 84.21%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News SentimentN/A News SentimentKiora Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPRX Stock News HeadlinesKiora Pharmaceuticals files $100M mixed securities shelfSeptember 16, 2025 | msn.comKiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 6, 2025 | theglobeandmail.comThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the verge of its biggest breakthrough yet — a revolutionary form of “Manifested AI” that Forbes has called a multi-trillion-dollar opportunity, potentially sparking a 25,000% growth market and setting up what he believes could be the greatest corporate comeback in history. | Brownstone Research (Ad)Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | finanznachrichten.deKiora Pharmaceuticals Highlights at Ophthalmology ConferenceAugust 13, 2025 | msn.comKiora (KPRX) Q2 Revenue Falls 100%August 8, 2025 | theglobeandmail.comKiora Pharmaceuticals Advances Retinal Disease PipelineAugust 8, 2025 | tipranks.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 8, 2025 | finanznachrichten.deSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $3.30 at the start of the year. Since then, KPRX stock has decreased by 23.3% and is now trading at $2.53. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its quarterly earnings results on Friday, August, 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. The business earned $0.75 million during the quarter, compared to analyst estimates of $0.75 million. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split before market open on Tuesday, June 11th 2024.The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. Who are Kiora Pharmaceuticals' major shareholders? Top institutional investors of Kiora Pharmaceuticals include AIGH Capital Management LLC (7.12%) and Stonepine Capital Management LLC (5.19%). Insiders that own company stock include Brian M Strem, Eric Joseph Daniels, Erin Parsons, Melissa Tosca, Aron Shapiro and Lisa Walters-Hoffert. View institutional ownership trends. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD). Company Calendar Last Earnings8/08/2025Today9/20/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPRX CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Kiora Pharmaceuticals$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+295.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.91) Trailing P/E RatioN/A Forward P/E Ratio1.98 P/E GrowthN/ANet Income$3.60 million Net MarginsN/A Pretax Margin-49,315.00% Return on Equity-47.17% Return on Assets-34.00% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$16.02 million Price / Sales0.54 Cash Flow$1.18 per share Price / Cash Flow2.14 Book Value$8.58 per share Price / Book0.29Miscellaneous Outstanding Shares3,430,000Free Float3,432,000Market Cap$8.68 million OptionableNot Optionable Beta-0.68 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:KPRX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.